Pilot Study of Pancreatic Cancer Screening

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT05058846
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Biospecimen Collection — PROCEDURE
    Undergo blood, tissue, and saliva collection
  • Magnetic Resonance Cholangiopancreatography — PROCEDURE
    Undergo MRCP
  • Magnetic Resonance Imaging — PROCEDURE
    Undergo MRI
  • Endoscopic ultrasound — PROCEDURE
    Undergo endoscopic ultrasound
  • Questionnaires — OTHER
    Complete the following questionnaires: Pancreatic Cancer Knowledge Survey, Pancreatic Cancer Worry Scale, Disease Specific Perceived Risk Survey, eGene Questionnaire

Study Details

This study investigates how often abnormal findings from routine magnetic resonance imaging occur in people with genetic mutations in BReast CAncer gene. (BRCA), ataxia telangiectasia mutated gene (ATM), or PALB2 screened for pancreatic cancer. This study may lead to a greater understanding of cancer and potentially, improvements in cancer screening and treatment.

Key Dates

Start date
Jan 20, 2022
Status verified
Apr 2025
Primary completion
Jan 31, 2032
Completion
Jan 31, 2032

Study Design

Enrollment
250 participants (estimated)

Arms

  • Arm: Group I: No strong family history of pancreatic cancer
    Participants in Group 1 consist of BRCA, ATM and PALB2 mutation carriers without a strong family history of pancreatic cancer and can choose to undergo annual magnetic resonance imaging (MRI)/Magnetic resonance cholangiopancreatography (MRCP) and EUS screening, or they may opt out of annual MRI screening. Participants also have the opportunity to co-enroll in the University of California, San Francisco (UCSF) BRCA Center Biorepository for biospecimen/biomarker collection and will complete surveys, including the optional eGene questionnaire, which involves co-enrollment in the eGene Study.
  • Arm: Group II: Strong family history of pancreatic cancer
    Participants in Group 2 consist of BRCA, ATM and PALB2 mutation carriers with a strong family history of pancreatic cancer. Participants may undergo annual MRI/MRCP screening and may also elect to get an endoscopic ultrasound (EUS) every other year. Participants also have the opportunity to co-enroll in the UCSF BRCA Center Biorepository for biospecimen/biomarker collection and will complete surveys, including the optional eGene questionnaire, which involves co-enrollment in the eGene Study.

Primary Outcome Measure

Proportion of participants with of abnormal magnetic resonance imaging (MRI) findings [ Time Frame: Up to 10 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California San FranciscoSan FranciscoCalifornia94143
Phu Lam
[email protected]
415-353-8337
[email protected]
877-827-3222
Pamela N Munster, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
University of California San Francisco· San Francisco, CA

Related Studies